Guiding structural heart interventions to increase safety and efficacy

Try TAVIguide

FEops
simulation platform

Our cloud-based simulation platform is designed to assist clinicians in preoperatively assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions

It also adds value to cardiovascular device companies developing and marketing novel medical device technologies.

Try TAVIguide

Patient-based
simulation

Using routine preoperative imaging data FEops creates a patient-based simulation model that allows to predict the interaction between a device and a patient's unique anatomy.

Our first product is the CE-marked TAVIguide.

Try TAVIguide

The TAVIguide
technology

The TAVIguide technology empowers clinicians to optimize personalized device selection and positioning. TAVIguide predicts the interaction between the TAVI device and the specific patient, combining routine preoperative CT imaging with advanced computer simulations.

Try it and get up to 3 TAVIguide analyses free of charge within one month (since first scan sent).

Try TAVIguide

TAVIguide
is easy

Clinical
evidence

Schultz et al. Patient-specific image-based computer simulation for the prediction of valve morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards SAPIEN.

EuroIntervention 2016; 11 1044-1052

de Jaegere et al. Patient-Specific Computer Modelling to Predict Aortic Regurgitation After Transcathether Aortic Valve Replacement.

JACC Card Intv 2016; 9 (5) 508-512

Videos

Case reports
& testimonials

  • Coming soon!

    There are no case reports available yet.

  • Dr Peter de Jaegere

    EMC, Rotterdam, NL

    I believe this technology will have an important clinical implication. It will allow the selection of both the type and size of the valve for a particular patient (tailored medicine), which will increase the safety and efficacy of TAVI.

  • Dr Azeem Latib

    San Rafaele, Milano, IT

    Ideally, as TAVI becomes standard of care even in low and intermediate risk patients, it would be great to take the guess-work out – to be able to simulate what is going to happen when you put the valve into that anatomy.

  • Dr Mark Monaghan

    King’s College, London, UK

    In order to make structural heart procedures more predictable, computational modeling is likely to have a critical role to play.  FEops have successfully developed technology that simulates the interaction between implanted devices and various cardiac structures.  We view this as a very exiting development in interventional cardiology.

  • Dr Carlos Ruiz

    Hackensack University Medical Center, New York, USA

    Pre-operatively simulating different scenarios of the intervention will undoubtedly play a key role in further reducing complications for structural heart interventions.

  • Dr Ronak Rajani

    Guy’s and St Thomas’, London, UK

    FEops are leading the way in image segmentation and computer modelling. With an emphasis on structural intervention, new solutions are being developed to enable clinicians to better plan for their procedures and to predict outcomes more robustly than historical geometric data alone.

Partners

Contact

FEops nv

Technologiepark 3
9052 Gent
Belgium

+32 9 281 26 83

Sign up for Product and Company Updates.

Management Team

Matthieu is a visionary entrepreneur with great people management and communication skills. Under his leadership FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in Engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. In 2009 he followed the general management program ‘Technology Transfer’ at Vlerick Leuven Gent Management School. Matthieu is author of several high-impact scientific publications.

Peter is a co-founder of FEops, and holds the position of Chief Technology Officer (CTO). He is internationally recognized for his groundbreaking work in using computer simulations to evaluate cardiovascular implants and procedures. Under his supervision, the TAVIguideTM technology has been transformed from an innovative idea into a CE marked techology. Peter received a PhD in biomedical engineering from Ghent University.

Tom is a healthcare industry professional bringing over 20y of experience in the medical industry to FEops. He held several high management level positions, managed Distributor Sales channels in over 30 countries across the world, predominantly in the field of interventional cardiology bringing novel, niche technology, such as Pressure Wire for Fractional Flow Reserve measurement to the market.

Board of Directors

Rob Michiels was elected as a member of the Company's Board of Directors in 2016.  He is a 30plus-year veteran of the US medical device industry, both in corporate positions and as a serial startup entrepreneur.  He most recently served as Chief Executive Officer of CardiAQ™ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation and which was acquired by Edwards Lifesciences late 2015.  He previously served as President and Chief Operating Officer (COO) of CoreValve; and as President and COO of InterVentional Technologies.  He helped drive both companies from cardiovascular start-ups to established market leaders, developing and marketing new and innovative interventional technologies which have strong synergies to the FEops story.  Rob Michiels is also a founding partner of CONSILIUM Associates, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Masters in business administration (MBA) from Indiana University

Alexandra Tolia is Senior Investment Manager at PMV, where she directs investments in innovative Life Sciences ventures. Since 2011 she has served as board member in several biotech companies, including eTheRNA, Multiplicom, FEops, iTeos Therapeutics and Apitope. Prior to PMV she led the investment strategy at Hunza Ventures, where she was instrumental in establishing the fund's biotech portfolio in Europe and the US. For over a decade before joining the investment industry, Alexandra built an international scientific career, pioneering drug development initiatives in neurodegeneration and cardiovascular diseases, and managing key alliances between academia and the pharmaceutical industry. Alexandra holds a PhD in Medical Sciences from the University of Leuven, a degree in Management from the Solvay Brussels School of Economics and Management and is the author of several high-impact scientific publications.

Marc Lambrechts (55) is Senior Investment Manager at Capricorn Venture Partners NV. Marc’s investment interests are related to technology fusion and more specifically ICT, digital healthcare, IoT and nanotechnology. Marc was in charge of the successful investments in a.o. Enfocus, FillFactory and Punch Powertrain. He serves on the board of FEops, Bluebee and Leuven.Inc Prior to joining Capricorn Venture Partners in March 1998 Marc served for six years as Senior Scientific Adviser at IWT and worked two years at the European R&D lab of Terumo Europe NV. Marc has a PhD in Electrical Engineering of the University of Leuven, more specifically on implantable biosensors.

Matthieu De Beule is a visionary entrepreneur with great people management and communication skills. Under his leadership FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in Engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. In 2009 he followed the general management program ‘Technology Transfer’ at Vlerick Leuven Gent Management School. Matthieu is author or co-author of over 100 scientific publications.

Peter is a co-founder of FEops, and holds the position of Chief Technology Officer (CTO). He is internationally recognized for his groundbreaking work in using computer simulations to evaluate cardiovascular implants and procedures. Under his supervision, the TAVIguideTM technology has been transformed from an innovative idea into a CE marked techology. Peter received a PhD in biomedical engineering from Ghent University.

Careers

FEops is a fast growing company developing cutting edge simulation technology for next generation planning of transcatheter structural heart interventions.

If you are looking forward to help us grow together with you, please do not hesitate and send your motivation letter and CV to info@feops.com

Apply Here

Now looking for

We welcome spontaneous applications for internships or a (future) position / vacancies to strengthen our R&D, operational and commercial activities.

News & Events

  • 15 09 2016

    TCT (Oct 29 - Nov 2, 2016)

    Surrounded by sharks, we are looking forward to present our latest results in the ‘Interventional innovations and best new technologies’ session on Sunday October 30th.

  • 01 09 2016

    London Valves (Sept 18-20, 2016)

    We will be attending the London Valves meeting in London soon. Don’t hesitate to schedule a meeting and go and check out the presentation of Nahib featuring our TAVIguide technology.

  • 02 08 2016

    H2020 SME Champions League

    FEops is proud to announce it successfully completed its H2020 SME Phase 1 project.

Press releases

  • 16 sep 2016

Study
anatomy

While it is vital to have quantitative information on the targeted cardiovascular anatomy when developing a new medical device, it is often difficult to find detailed information on the geometry of the anatomies (average values and standard deviations of diameters, amount of tapering, angles, etc.)

FEops has developed unique tools to perform automated measurements on 3D anatomical reconstructions (e.g. CT- or MRI-based), which allow the data of a large number of patients to be analyzed within a reasonable period. Through our clinical network, we can assist companies in finding appropriate medical image data.

Prove
your concept

New device ideas can be evaluated by manufacturing prototypes and subsequent bench testing. Regularly this is time-consuming and not always cost-efficient. Alternatively, computer simulations can be used for this purpose reducing the amount of prototypes to be built and speeding-up the design cycle.

Due to our extensive experience with intravascular devices, we rapidly understand new device concepts. We offer the most advanced simulations, in which the interaction of the new device with a realistic vascular model can be investigated, giving extremely valuable insights into the device behaviour. Based on these realistic simulations, figures and animations can be created that can help start-up companies to attract investors.

Design
& development

During the early phases of the design cycle it is not a sinecure to select the most promising device design alternative to further optimize. Computer simulations can help with this selection and reduce the number of prototypes to be built and thus speed up the design cycle significantly.

Thanks to its extensive experience with intravascular devices, FEops provides developers with advanced computer simulations to evaluate new device performance (e.g. radial strength, flexibility, crimpability, deployment behavior, etc.). The simulations help to explore different design alternatives without having to manufacture prototypes. With these virtual bench tests, we can also perform a virtual Design Of Experiments (DOE) and determine the optimal device design.

Patient-specific
modeling

Merging simulation technologies with medical imaging opens the door to patient-tailored therapy.

FEops provides unique simulation technology to implant intravascular devices within patient-based models and to visualize the interaction of the new device with a realistic vascular model. The technology allows medical device manufacturers to evaluate new devices in multiple patient-based anatomical models prior to conducting expensive and risky animal or clinical trials or to gain insights into device behavior during a clinical trial.

Regulatory
approval

Accelerated in-vitro fatigue testing is expensive and time-consuming. Finite element simulations can help to reduce the amount of real fatigue tests to a minimum, as it can be used to detect the worst-case device size and loading conditions.

FEops performs accurate stress / strain analyses to determine fatigue safety factors following ISO Standards (e.g. ISO 25539) and FDA guidelines. This information is then used to perform a limited number of accelerated in-vitro fatigue tests.

Marketing
& education

llustrating the functioning and benefits of a device is crucial for successful marketing, but also to educate people on the device characteristics and its use.

FEops’ advanced computer models can be used to generate realistic animations and high-quality images of medical devices, used for marketing and educational services. Moreover, start-up companies can use our computer simulations as a basis for figures and animations that can help attract investors. FEops is experienced in reverse engineering products (i.e. building models starting from a device sample). In this way, we can compare new technologies with existing products on the market.

TOP